CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $48.38M, above the global median of $18.73M
- PositionOperating margin is 42.3%, higher than 95% of its Biotechnology peers (median -38%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
671.04MUSDvs all stocks (USD)
Trailing P/E
11.87xvs Biotechnology peers
Revenue (TTM)
136.07MUSDvs all stocks (USD)
Profit Margin
42.82%vs Biotechnology peers
Beta
0.9510xvs all stocks
52-Week Change
18.45%vs all stocks
Market Capitalization
671.04MUSDvs all stocks (USD)
Enterprise Value
435.52MUSDvs all stocks (USD)
Trailing P/E
11.87xvs Biotechnology peers
Forward P/E
10.25xvs Biotechnology peers
PEG Ratio
-0.1338xvs Biotechnology peers
Price to Sales (TTM)
4.82xvs Biotechnology peers
Price to Book (MRQ)
3.01xvs Biotechnology peers
Enterprise to Revenue
3.20xvs Biotechnology peers
Enterprise to EBITDA
10.74xvs Biotechnology peers
Gross Margin
96.16%vs Biotechnology peers
Profit Margin
42.82%vs Biotechnology peers
Operating Margin
42.30%vs Biotechnology peers
Return on Assets (TTM)
8.74%vs Biotechnology peers
Return on Equity (TTM)
34.80%vs Biotechnology peers
Revenue (TTM)
136.07MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.37USDUpdated Sep 29, 2026Quarterly Revenue Growth
53.30%vs Biotechnology peers
Gross Profit (TTM)
129.89MUSDvs all stocks (USD)
EBITDA (TTM)
50.73MUSDvs all stocks (USD)
Net Income (TTM)
57.25MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-88.30%vs Biotechnology peers
Operating Cash Flow (TTM)
33.40MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
48.38MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 29, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
106.47MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
16.48MUSDFY2025 · Dec 31, 2025Gross Profit
89.99MUSDFY2025 · Dec 31, 2025Operating Income
-4.23MUSDvs all stocks (USD)
Pre-tax Income
86.68MUSDFY2025 · Dec 31, 2025Income Tax Expense
3.45MUSDFY2025 · Dec 31, 2025Net Income
83.23MUSDFY2025 · Dec 31, 2025EBIT
94.66MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
6.77MUSDFY2025 · Dec 31, 2025Research & Development
12.74MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
77.62MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
6.95MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
7.98MUSDFY2025 · Dec 31, 2025EPS (Basic)
1.40USDFY2025 · Dec 31, 2025EPS (Diluted)
1.35USDFY2025 · Dec 31, 2025Basic Shares Outstanding
55.31MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
55.31MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
83.23MUSDFY2025 · Dec 31, 2025Operating Cash Flow
98.71MUSDFY2025 · Dec 31, 2025Free Cash Flow
98.32MUSDDerived from operating cash flow minus capital expenditure. This filing charges 4.05M of depreciation against 387K of capital expenditure, and its own free-cash-flow line reads -2.43M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
62.41MUSDFY2025 · Dec 31, 2025Interest Paid
5.33MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
83.23MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
4.05MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
3.45MUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.63MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.33MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-11.98MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
4.00MUSDFY2025 · Dec 31, 2025Capital Expenditures
-387.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-309.99MUSDFY2025 · Dec 31, 2025Sale of Investments
328.50MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
18.13MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-372.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
8.27MUSDFY2025 · Dec 31, 2025Shares Outstanding
59.34MSharesUpdated Sep 29, 2026Float Shares
53.90MSharesUpdated Sep 29, 2026Shares Short
5.74MSharesUpdated Sep 29, 2026Short Ratio
6.77daysvs all stocks
Short % of Shares Outstanding
9.78%vs all stocks
% Held by Insiders
1.26%vs all stocks
% Held by Institutions
77.29%vs all stocks
Total Cash (MRQ)
221.57MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.73USDUpdated Sep 29, 2026Total Debt (MRQ)
1.50MUSDvs all stocks (USD)
Current Ratio (MRQ)
5.17xvs Biotechnology peers
Book Value per Share (MRQ)
3.67USDUpdated Sep 29, 2026Total Assets
284.73MUSDvs all stocks (USD)
Total Current Assets
223.01MUSDFY2025 · Dec 31, 2025Total Liabilities
130.07MUSDFY2025 · Dec 31, 2025Total Non-current Assets
61.72MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
90.80MUSDFY2025 · Dec 31, 2025Total Current Liabilities
39.28MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
62.41MUSDFY2025 · Dec 31, 2025Other Short-term Investments
128.60MUSDFY2025 · Dec 31, 2025Accounts Receivable
9.88MUSDFY2025 · Dec 31, 2025Inventory
1.74MUSDFY2025 · Dec 31, 2025Accounts Payable
2.48MUSDFY2025 · Dec 31, 2025Short-term Debt
419.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
13.55MUSDFY2025 · Dec 31, 2025Long-term Debt
62.79MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
11.41MUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-422.06MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
154.66MUSDvs all stocks (USD)
Treasury Stock
10.98MUSDFY2025 · Dec 31, 202552-Week Low
8.01USDUpdated Sep 29, 202652-Week High
15.04USDUpdated Sep 29, 202652-Week Change
18.45%vs all stocks
Beta
0.9510xvs all stocks
50-Day MA
11.49USDUpdated Sep 29, 2026200-Day MA
10.50USDUpdated Sep 29, 2026Avg 10-Day Volume
872.13KSharesUpdated Sep 29, 2026Avg 30-Day Volume
858.55KSharesUpdated Sep 29, 2026Diluted EPS (TTM)
0.9300USDUpdated Sep 29, 2026Other Income / Expense
91.94MUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 42.3%, higher than 95% of its Biotechnology peers (median -38%)Significant
Operating margin: 0.42Industry median: -0.38Industry P95: 0.40Peers compared: 260
Profit margin is 42.8%, higher than 95% of its Biotechnology peers (median -47.7%)Significant
Profit margin: 0.43Industry median: -0.48Industry P95: 0.42Peers compared: 260
Return on equity is 34.8%, higher than 95% of its Biotechnology peers (median -22.3%)Significant
Return on equity: 0.35Industry median: -0.22Industry P95: 0.23Peers compared: 260
Financial Health
Altman Z-Score 3.27: safe zoneNotable
Altman Z-Score: 3.27
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $48.38M, above the global median of $18.73MNotable
Levered free cash flow (USD): 48,381,124Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Fuan Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Climb Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Senores Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hangzhou AGS Medtech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sinotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Kinetic Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Hansen Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MiMedx Group, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nuvectis Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Henan Taloph Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
MPC Container Ships ASA
4 interpretationsMinimal Tax and Interest DragFCF Ratios ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin Elevated
Global Ship Lease Inc.
4 interpretationsMinimal Tax and Interest DragFCF Ratios ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin Elevated
Krystal Biotech Inc.
4 interpretationsMinimal Tax and Interest DragFCF Ratios ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin Elevated